Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400M6Z3
Pharmaceuticals
OTC Markets Traded| Market Cap | 93.78B 109B 87.74B 80.21B 151B 10,479B 153B 1,038B 404B 5,262B 411B 402B 17,409B | P/E 2026 * |
12.5x | P/E 2027 * | 10.9x |
|---|---|---|---|---|---|
| Enterprise Value | 105B 123B 98.45B 90.01B 170B 11,759B 172B 1,165B 453B 5,904B 461B 451B 19,536B | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 2.01x |
| Free-Float |
88.34% | Yield 2026 * |
5.43% | Yield 2027 * | 5.75% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 57 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 110B | |
| -0.67% | +5.39% | +79.33% | +127.54% | 1,119B | |
| +1.04% | +4.07% | +53.04% | +65.39% | 651B | |
| -0.17% | +5.67% | +27.45% | +80.40% | 468B | |
| -1.38% | +4.31% | +41.64% | +41.08% | 374B | |
| -0.52% | +3.53% | +24.32% | +40.27% | 302B | |
| -1.06% | +5.67% | +1.19% | +12.44% | 259B | |
| +1.03% | +5.83% | +53.86% | +72.96% | 238B | |
| -0.53% | +1.54% | -17.77% | -54.10% | 208B | |
| +0.42% | +5.63% | +28.55% | +92.24% | 181B | |
| Average | -0.20% | +5.17% | +32.40% | +53.14% | 422.21B | |
| Weighted average by Cap. | -0.16% | +5.40% | +45.70% | +72.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.59B 55.53B 44.52B 40.71B 76.81B 5,318B 77.63B 527B 205B 2,670B 209B 204B 8,835B | 50.7B 59.16B 47.43B 43.36B 81.82B 5,664B 82.69B 561B 218B 2,844B 222B 217B 9,411B |
| Net income | 7.91B 9.23B 7.4B 6.77B 12.77B 884B 12.9B 87.57B 34.05B 444B 34.66B 33.91B 1,468B | 9.24B 10.79B 8.65B 7.91B 14.92B 1,033B 15.08B 102B 39.79B 519B 40.5B 39.62B 1,716B |
| Net Debt | 11.46B 13.37B 10.72B 9.8B 18.49B 1,280B 18.69B 127B 49.32B 643B 50.2B 49.11B 2,127B | 8.3B 9.69B 7.77B 7.1B 13.4B 928B 13.54B 91.92B 35.74B 466B 36.38B 35.59B 1,541B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
